RadNet, Inc. (NASDAQ: RDNT) is a Healthcare company in the Medical - Diagnostics & Research industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | -0.27 | Insider Own | 10.62% | Shs Outstand | 78.63M | Perf Week | 0.68% |
| Market Cap | 5.98B | Forward P/E | 85.71 | EPS next Y | 0.89 | Insider Trans | -0.62% | Shs Float | 70.36M | Perf Month | 0.61% |
| Enterprise Value | 7.36B | PEG | - | EPS next Q | 0.21 | Inst Own | - | Short Float | 14.13% | Perf Quarter | 41.42% |
| Income | -21.00M | P/S | 2.63 | EPS this Y | 290.48% | Inst Trans | - | Short Ratio | 12.02 | Perf Half Y | 21.33% |
| Sales | 2.27B | P/B | 4.29 | EPS next Y | 72.41% | ROA | -0.50% | Short Interest | 9.94M | Perf YTD | 6.52% |
| Book/sh | 17.73 | P/C | 8.23 | EPS next 5Y | 52.11% | ROE | -1.95% | 52W High | 85.84 -11.46% | Perf Year | 1.06% |
| Cash/sh | 9.23 | P/FCF | - | EPS past 3/5Y | - | ROIC | 1.38% | 52W Low | 50.82 49.55% | Perf 3Y | 176.06% |
| Dividend Est. | - | EV/EBITDA | 21.85 | Sales past 3/5Y | 12.57% 13.73% | Gross Margin | 9.70% | Volatility | 3.72% 3.43% | Perf 5Y | 158.50% |
| Dividend TTM | - | EV/Sales | 3.24 | EPS Y/Y TTM | -821.93% | Oper. Margin | 4.00% | ATR (14) | 2.70 | Perf 10Y | 987.27% |
| Dividend Ex-Date | - | Quick Ratio | 1.48 | Sales Y/Y TTM | 24.04% | Profit Margin | -0.93% | RSI (14) | 55.34 | Recom | 2.09 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.48 | EPS Q/Q | -6.45% | SMA20 | 1.00% | Beta | 1.39 | Target Price | 65.00 |
| Payout | 0.00% | Debt/Eq | 1.32 | Sales Q/Q | 25.10% | SMA50 | 7.58% | Rel Volume | 1.59 | Prev Close | 77.78 |
| Employees | 9,060 | LT Debt/Eq | 1.31 | Earnings | Nov 09 | SMA200 | 15.53% | Avg Volume | 807.76K | Price | 76.00 |
| IPO Date | Jan 03, 1997 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 43.97% 1.94% | Net Debt/EBITDA | 4.32 | Volume | 1,284,408 | Change | -2.29% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| May-20-26 | Reiterated | Barclays | Overweight | $79 → $65 |
| Mar-03-26 | Reiterated | Jefferies | Buy | $100 → $91 |
| Jan-09-26 | Initiated | KeyBanc | Overweight | $92 |
| Jan-08-26 | Initiated | KeyBanc | Overweight | $92 |
| Dec-17-25 | Reiterated | Truist Financial | Buy | $81 → $90 |
| Nov-14-25 | Reiterated | Raymond James | Strong Buy | $95 |
| Sep-03-25 | Reiterated | Truist Securities | Buy | $74 → $81 |
| Jul-10-25 | Reiterated | Truist Financial | Buy | $88 → $74 |
| Mar-05-25 | Upgrade | Raymond James | Outperform → Strong Buy | |
| Jan-22-25 | Reiterated | Truist Securities | Buy | $94 → $88 |
RadNet, Inc. operates as a prominent healthcare services company specializing in outpatient diagnostic imaging across the United States. Their comprehensive offerings span a broad spectrum of advanced imaging techniques, including magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, and general diagnostic radiology, along with various specialized procedures. Beyond direct patient services, the company also plays a significant role in developing and marketing specialized computerized systems for the diagnostic imaging sector, such as picture archiving communication systems (PACS) and associated support. Furthermore, RadNet is at the forefront of integrating artificial intelligence (AI) solutions, designing and deploying AI suites to augment radiologist interpretation, particularly in mammography, and extending these AI capabilities to lung and prostate cancer diagnostics. As of December 31, 2021, its operational footprint included ownership and management of 347 centers situated across seven states: Arizona, California, Delaware, Florida, Maryland, New Jersey, and New York. Established in 1981, the company maintains its headquarters in Los Angeles, California.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 2,270 | 2,040 | 1,830 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 2,049 | 1,949 | 1,581 | — | — | — | — | — | — | |
| Gross Profit | 220 | 91 | 249 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 0 | 0 | 0 | — | — | — | — | — | — | |
| Research and Development | 0 | 0 | 0 | — | — | — | — | — | — | |
| Other Operating Expense | 130 | 0 | 144 | — | — | — | — | — | — | |
| Operating Income | 91 | 91 | 105 | — | — | — | — | — | — | |
| Interest Expense | 71 | 70 | 80 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 15 | 11 | 20 | — | — | — | — | — | — | |
| Net Income Before Taxes | 35 | 32 | 45 | — | — | — | — | — | — | |
| Income Taxes | 15 | 15 | 6 | — | — | — | — | — | — | |
| Consolidated Net Income | -21 | -19 | 3 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 19 | 17 | 39 | — | — | — | — | — | — | |
| Net Income | -21 | -19 | 3 | — | — | — | — | — | — | |
| EPS (Recurring) | -0.27 | -0.25 | 0.04 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -0.27 | -0.25 | 0.04 | — | — | — | — | — | — | |
| EPS (Diluted) | -0.27 | -0.25 | 0.04 | — | — | — | — | — | — | |
| EBITDA | 337 | 254 | 263 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | 1,867.38 | — | — | — | — | — | — | |
| Price To Sales Ratio | 2.61 | 2.62 | 2.79 | — | — | — | — | — | — | |
| Gross Margin | 9.69 | 4.46 | 13.61 | — | — | — | — | — | — | |
| Operating Margin | 4.01 | 4.46 | 5.74 | — | — | — | — | — | — | |
| Net Margin | -0.93 | -0.93 | 0.16 | — | — | — | — | — | — | |
| Shares Outstanding | 78 | 75 | 73 | — | — | — | — | — | — | |
| Market Capitalization | 5,928 | 5,351 | 5,098 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| SWARTZ DAVID L | Director | Jun 18 '26 | Sale | 53.89 | 2,699 | 145,449 | 177,013 | Jun 22 |
| Wesdorp Cornelis | Pres & CEO, Digital Health | Jun 16 '26 | Sale | 58.11 | 4,750 | 276,023 | 69,075 | Jun 18 |
| Forthuber Stephen M | Pres & CEO-Eastern Operations | Jun 15 '26 | Sale | 58.16 | 44,067 | 2,562,911 | 507,199 | Jun 16 |
| Berger Howard G | President, CEO | May 05 '26 | Option Exercise | 18.64 | 25,992 | 484,491 | 498,405 | May 06 |
| Sorensen Alma Gregory | Chief Strategy Officer | Mar 19 '26 | Sale | 62.20 | 15,000 | 933,014 | 1,208,923 | Mar 23 |
| Sorensen Alma Gregory | Chief Strategy Officer | Mar 18 '26 | Sale | 62.15 | 15,000 | 932,280 | 1,223,923 | Mar 18 |
| Sorensen Alma Gregory | Chief Strategy Officer | Mar 10 '26 | Option Exercise | 0.00 | 62,964 | 0 | 1,244,842 | Mar 12 |
| STOLPER MARK | EVP, Chief Financial Officer | Dec 10 '25 | Option Exercise | 6.07 | 35,703 | 216,717 | 103,715 | Dec 12 |
| Katz David Jeffrey | EVP and Chief Legal Officer | Dec 10 '25 | Option Exercise | 29.44 | 3,396 | 99,978 | 71,577 | Dec 12 |
| Forthuber Stephen M | Pres & COO-Eastern Operations | Dec 05 '25 | Sale | 78.33 | 45,088 | 3,531,849 | 529,221 | Dec 09 |
| Forthuber Stephen M | Pres & COO-Eastern Operations | Dec 03 '25 | Option Exercise | 6.07 | 39,127 | 237,501 | 574,309 | Dec 03 |
| Berger Howard G | President, CEO | Nov 19 '25 | Option Exercise | 18.64 | 129,961 | 2,422,473 | 348,412 | Nov 21 |
| Patel Mital | EVP of Fin Planning, CAO | Nov 19 '25 | Sale | 80.05 | 15,080 | 1,207,154 | 180,138 | Nov 19 |
| Patel Mital | EVP of Fin Planning, CAO | Nov 18 '25 | Sale | 80.00 | 9,920 | 793,600 | 195,218 | Nov 19 |
| Patel Mital | EVP of Fin Planning, CAO | Nov 17 '25 | Sale | 76.06 | 25,000 | 1,901,500 | 205,138 | Nov 19 |